153 related articles for article (PubMed ID: 21371597)
1. Fragment screening purely with protein crystallography.
Spurlino JC
Methods Enzymol; 2011; 493():321-56. PubMed ID: 21371597
[TBL] [Abstract][Full Text] [Related]
2. Crystallographic fragment screening.
Badger J
Methods Mol Biol; 2012; 841():161-77. PubMed ID: 22222452
[TBL] [Abstract][Full Text] [Related]
3. Designing a diverse high-quality library for crystallography-based FBDD screening.
Tounge BA; Parker MH
Methods Enzymol; 2011; 493():3-20. PubMed ID: 21371585
[TBL] [Abstract][Full Text] [Related]
4. Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
Lange G; Lesuisse D; Deprez P; Schoot B; Loenze P; Bénard D; Marquette JP; Broto P; Sarubbi E; Mandine E
J Med Chem; 2003 Nov; 46(24):5184-95. PubMed ID: 14613321
[TBL] [Abstract][Full Text] [Related]
5. Hsp90 inhibitors and drugs from fragment and virtual screening.
Roughley S; Wright L; Brough P; Massey A; Hubbard RE
Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
[TBL] [Abstract][Full Text] [Related]
6. Label-free primary screening and affinity ranking of fragment libraries using parallel analysis of protein panels.
Hämäläinen MD; Zhukov A; Ivarsson M; Fex T; Gottfries J; Karlsson R; Björsne M
J Biomol Screen; 2008 Mar; 13(3):202-9. PubMed ID: 18270366
[TBL] [Abstract][Full Text] [Related]
7. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.
Giannetti AM
Methods Enzymol; 2011; 493():169-218. PubMed ID: 21371592
[TBL] [Abstract][Full Text] [Related]
8. Fragment-based screening using X-ray crystallography and NMR spectroscopy.
Jhoti H; Cleasby A; Verdonk M; Williams G
Curr Opin Chem Biol; 2007 Oct; 11(5):485-93. PubMed ID: 17851109
[TBL] [Abstract][Full Text] [Related]
9. Electron density guided fragment-based drug design--a lead generation example.
Abad MC; Gibbs AC; Zhang X
Methods Enzymol; 2011; 493():487-508. PubMed ID: 21371603
[TBL] [Abstract][Full Text] [Related]
10. How to avoid rediscovering the known.
Kuo LC
Methods Enzymol; 2011; 493():159-68. PubMed ID: 21371591
[TBL] [Abstract][Full Text] [Related]
11. Fragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitors.
Drinkwater N; Vu H; Lovell KM; Criscione KR; Collins BM; Prisinzano TE; Poulsen SA; McLeish MJ; Grunewald GL; Martin JL
Biochem J; 2010 Oct; 431(1):51-61. PubMed ID: 20642456
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design.
Tsao DH; Sutherland AG; Jennings LD; Li Y; Rush TS; Alvarez JC; Ding W; Dushin EG; Dushin RG; Haney SA; Kenny CH; Malakian AK; Nilakantan R; Mosyak L
Bioorg Med Chem; 2006 Dec; 14(23):7953-61. PubMed ID: 16919463
[TBL] [Abstract][Full Text] [Related]
13. High-throughput fragment screening by affinity LC-MS.
Duong-Thi MD; Bergström M; Fex T; Isaksson R; Ohlson S
J Biomol Screen; 2013 Feb; 18(2):160-71. PubMed ID: 22983162
[TBL] [Abstract][Full Text] [Related]
14. Using computational techniques in fragment-based drug discovery.
Desjarlais RL
Methods Enzymol; 2011; 493():137-55. PubMed ID: 21371590
[TBL] [Abstract][Full Text] [Related]
15. HierVLS hierarchical docking protocol for virtual ligand screening of large-molecule databases.
Floriano WB; Vaidehi N; Zamanakos G; Goddard WA
J Med Chem; 2004 Jan; 47(1):56-71. PubMed ID: 14695820
[TBL] [Abstract][Full Text] [Related]
16. Screening Ligands by X-ray crystallography.
Davies DR
Methods Mol Biol; 2014; 1140():315-23. PubMed ID: 24590727
[TBL] [Abstract][Full Text] [Related]
17. Fragment-based screening using surface plasmon resonance technology.
Perspicace S; Banner D; Benz J; Müller F; Schlatter D; Huber W
J Biomol Screen; 2009 Apr; 14(4):337-49. PubMed ID: 19403917
[TBL] [Abstract][Full Text] [Related]
18. Lead generation and examples opinion regarding how to follow up hits.
Orita M; Ohno K; Warizaya M; Amano Y; Niimi T
Methods Enzymol; 2011; 493():383-419. PubMed ID: 21371599
[TBL] [Abstract][Full Text] [Related]
19. Efficiency of hit generation and structural characterization in fragment-based ligand discovery.
Larsson A; Jansson A; Åberg A; Nordlund P
Curr Opin Chem Biol; 2011 Aug; 15(4):482-8. PubMed ID: 21724447
[TBL] [Abstract][Full Text] [Related]
20. Experimental validation of a fragment library for lead discovery using SPR biosensor technology.
Elinder M; Geitmann M; Gossas T; Källblad P; Winquist J; Nordström H; Hämäläinen M; Danielson UH
J Biomol Screen; 2011 Jan; 16(1):15-25. PubMed ID: 21149860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
